Advertisement

U.S. Markets open in 1 hr 2 mins

S&P Futures
5,894.50
-2.00(-0.03%)
Dow Futures
43,491.00
-77.00(-0.18%)
Nasdaq Futures
20,525.25
+31.50(+0.15%)
Russell 2000 Futures
2,319.20
+5.60(+0.24%)
Crude Oil
67.23
+0.21(+0.31%)
Gold
2,602.70
+32.60(+1.27%)

Fate Therapeutics, Inc. (FATE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

2.0200

-0.0600

(-2.88%)

At close: 04:00PM EST

2.3200

+0.30

(+14.85%)

Pre-Market:

08:27AM EST

Trade prices are not sourced from all markets

All

GlobeNewswire
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
27-year-old African American-Asian Woman with Active Lupus Nephritis Achieved DORIS Clinical Remission; Patient Remains On-study, in Clinical Remission, and Free of All Immunosuppressive Therapies Patient Treated with Fludarabine-free Conditioning and Single-dose FT819; Favorable Safety Profile with No Grade ≥3 Adverse Events and No Events of CRS, ICANS, or GvHD Reconstituted B Cell Compartment Predominantly Consists of Naïve, Non-class Switched B Cells with Deep Depletion of Aberrant B Cells an
GlobeNewswire
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
Phase 1 Basket Study for B Cell-mediated Autoimmune Diseases to Assess FT522 as Add-on to Standard-of-care Induction and Maintenance Regimens without Conditioning Chemotherapy Initial Phase 1 Clinical Data in Relapsed / Refractory B-cell Lymphoma Show Favorable Safety Profile, Complete Responses, and Persistence of FT522 Live Cells Selective Targeting and Reduction of CD19+ B Cells Observed with Each FT522 Dose in Study’s First Low-dose Cohort without Conditioning Chemotherapy, Supporting Novel